Projects

GNA NOW

A European collaboration progressing Gram-Negative antibiotics from lead optimization up to completion of Phase I trials

Antimicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing many of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise.

icon_Hands 11


partners throughout Europe

icon_Money € 31 M


funding from IMI, EFPIA

Under the global umbrella of the IMI’s AMR Accelerator, the GNA NOW consortium (Gram-Negative Antibacterials NOW) will work on bringing together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Ultimately, the goal of GNA NOW is to operate a consortium of experts, representing all the critical skills and experience required to progress potential Gram(-) antibiotics from lead optimisation up to completion of Phase I trials. You can read more about the program on the AMR Accelerator website.

Operational and scientific leadership

As a neutral party with no conflicting interests, Lygature ensures that the agreed pre-set objectives of the consortium are reached within the six-year project term. In the particular complex and dynamic setting of GNA NOW, with multiple compound owners, the multi-consortia AMR Accelerator structure and the ambitious project goals, many of Lygature’s qualities are mobilized, including:

  • Operational coordination. Lygature leverages the vast experiences of managing public-private partnerships, interactions with IMI and stakeholder engagement to provide structure and process guidance.
     
  • Scientific leadership. As coordinator of the GNA NOW grant, Lygature is co-responsible for strategic decisions regarding resources, scientific output, and progress towards the clinic, including attrition and replacement programmes.
     
  • Agreement support. Lygature provides support in translation of the project in clear contractual language and well-balanced rights and obligations of all partners. Lygature will monitor the continued adequacy of the agreement and guide, if required, accession of additional programmes.
     
  • Stakeholder engagement. With the aim to contribute significantly to preclinical antibacterial development in the widest sense, Lygature contributes with best practices and support for capacity and knowledge exchange, funder interactions, and public patient involvement.

GNA NOW contributes to Lygature’s mission of accelerating the development of new treatments with important medical needs and a high societal impact. Lygature provides extensive management capabilities, and expertise as a custodian of trust, to move this multi-stakeholder research project forward.

Lygature together with

Project updates


  • GNA NOW off to a great start in battling antimicrobial resistance

    GNA NOW (Gram-Negative Antibiotic NOW) started on July 1st under the AMR Accelerator umbrella and the project kicked off with a meeting on July 4th in Utrecht, where project members met in person for the first time. The project, funded by the Innovative Medicines Initiative (IMI) and industry partner Evotec’s in-kind contributions, aims to operate a consortium of experts, representing all the critical skills and experience required to progress new chemical entities for Gram-negative bacterial infections with the aim to produce two drug candidates and conduct one first-in-human study.

    All eleven partners participating in GNA NOW were present at the kick-off meeting, some joining via video-link. An introduction game where participants had to pair profiles with the right names and faces allowed for some good conversations among the participants and insights in each other’s competence right away. It certainly also underlined that this consortium is composed of people burning for combatting antimicrobial resistance.